← Leaderboards
Noll L. Campbell
Purdue University
$4,010,266
Attributed
$4,010,266
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $692K · FY2014–23$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,010,266 · 2
By mechanism
R01$3,281,773 · 1
K23$728,493 · 1
Top collaborators
No co-investigators on record.
Most similar at Purdue University
Same institution · by research overlap
- Young L Kim$2,188,117
- Kenneth Stuart Henry$5,103,345
- Peristera Paschou$3,018,971
- Martin Chieng Were$1,695,510
- Xiaofeng Wang$299,999
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposHigh RiskDesignMedical SpecialtiesPatient Self-ReportS DiseaseEpidemiologyEnrollmentExposure ToImpaired CognitionMonitorParticipantDementiaPharmaceutical PreparationsCognitionComorbidityAnti-CholinergicsElderlyCognitiveCaringHealthcare SystemsPrimary Health CareMeasurementComplement
Grant awards (10)
Reducing Risk of Dementia through De-prescribing (R2D2)$636,378
R01 · FY2023 · AG · contact PI
Reducing Risk of Dementia through De-prescribing (R2D2)$642,694
R01 · FY2022 · AG · contact PI
Reducing Risk of Dementia through De-prescribing (R2D2)$655,365
R01 · FY2021 · AG · contact PI
Reducing Risk of Dementia through De-prescribing (R2D2)$655,365
R01 · FY2020 · AG · contact PI
Reducing Risk of Dementia through De-prescribing (R2D2)$691,971
R01 · FY2019 · AG · contact PI
Evaluating the Adverse Cognitive Effects of Medications$140,665
K23 · FY2018 · AG · contact PI
Evaluating the Adverse Cognitive Effects of Medications$142,448
K23 · FY2017 · AG · contact PI
Evaluating the Adverse Cognitive Effects of Medications$142,448
K23 · FY2016 · AG · contact PI
Evaluating the Adverse Cognitive Effects of Medications$150,466
K23 · FY2015 · AG · contact PI
Evaluating the Adverse Cognitive Effects of Medications$152,466
K23 · FY2014 · AG · contact PI